Cagrilintide
AM-833, Long-acting amylin analogue
A long-acting amylin receptor agonist used for obesity and type 2 diabetes treatment by enhancing satiety, reducing food intake, and aiding weight loss.
Completed
PHASE3
NCT05394519
A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Not Yet Recruiting
PHASE3
NCT07253285
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Completed
NA
NCT00855439
Evaluation of Exenatide in Patients With Diabetic Neuropathy
University of Michigan
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE2
NCT04982575
Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE3
NCT06323161
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE3
NCT05813925
A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE1
NCT06403761
Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE3
NCT07011667
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE1
NCT07010432
The Role of the Amylin Analogue Cagrilintide in Bone Metabolism
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE2
NCT03856047
Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE2
NCT06797869
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE1
NCT07184086
A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE1
NCT06207877
A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE3
NCT05567796
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE3
NCT05669755
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE1
NCT06716307
A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE3
NCT06534411
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE3
NCT06221969
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025